A Randomized, Open Label, 2-Period Crossover Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate

Trial Profile

A Randomized, Open Label, 2-Period Crossover Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2009

At a glance

  • Drugs PF 5212371; Tolbutamide
  • Indications Osteoarthritis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 11 Aug 2009 Actual end date changed from Jul 2006 to Aug 2006 as reported by ClinicalTrials.gov.
    • 16 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top